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OBJECTIVES: Evaluation of traditional Chinese medicines/complementary and alter-
native medicines (TCM/CAM) is generally difﬁ cult because their effectiveness might 
be confounded by multiple factors. It precludes the rational use of such therapies. In 
this article, we share our experiences of both retrospective and prospective outcome
studies to provide evidence for safety proﬁ les of TCM products and test their effective-
ness. METHODS: & RESULTS: We conducted retrospective observational studies on
the reimbursement database of National Health Insurance of Taiwan to explore the 
prevalent therapies of TCM and identify potential adverse effects and found that about 
64.2% of people in Taiwan ever used TCM during 1997–2004, and prescriptions 
containing Radix Paeoniae and Radix Glycyrrhizae were associated with increased
risks of hospitalization for acute hepatitis. We also documented that people taking 
more than 30 g of Mu-Tong or 60 g of Fangchi were signiﬁ cantly associated with
chronic kidney disease. In addition, two prospective observational studies of new
invented formula-TMN-1 and traditional formula-DJS (Duhuo Jisheng Tang) demon-
strated that 12 weeks of TMN-1 therapy was a viable alternative treatment for 
menopausal syndrome in perimenopausal women; and 4 weeks of DJS therapy appar-
ently reduced pain and stiffness for patients with osteoarthritis of knees, but seemed 
to be ineffective in treating ﬂ accidity of knees or aversion to cold. CONCLUSIONS:
Outcome researches can not only help developing safety proﬁ les of TCM/CAM, but 
also provide evidence for modifying guidelines of clinical application. As more evi-
dence is accumulated and synthesized, physicians trained in conventional medicine
would be encouraged to use such medicines rationally.
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OBJECTIVES: Tubal ligation is highly efﬁ cacious at preventing pregnancies; however
it is considered irreversible, resulting in information requests about reversal or in vitro 
fertilization. The study objective is to compare the cost-effectiveness of LNG-IUS 
(MIRENA) and tubal ligation on contraception from a US payer’s perspective. 
METHODS: A Markov model was developed to simulate costs savings associated 
with switching 2% of women (N  2841) requiring contraception from tubal ligation 
(31.9–29.9%) to LNG-IUS (4.3–6.3%). The study population was based on a 1 
million member plan and included females age 18–45 who desire contraception (N 
142,031). Method failure (resulting in ectopic pregnancy, spontaneous abortion,
induced abortion, or birth), adverse events, and resource utilization were derived from 
the literature and supplemented with expert opinion when needed. Contraception drug
cost for LNG-IUS was taken from Medi-Span Master 2007 Drug Database. Cost of 
tubal ligation was derived based on resource utilization and the national payment for 
relevant diagnosis-related groups (DRGs) from the Ingenix DRG Expert. Physician
service and ofﬁ ce visits costs were obtained from the average fees associated with the 
2007 Procedural Terminology (CPT) codes. Both costs and effectiveness were dis-
counted at 3% per year. Model outputs included pharmacy, medical, side effects, 
failure and total costs to the health plan for a two and ﬁ ve year time horizon. 
RESULTS: An increase of 2% of LNG-IUS resulted in a total cost savings of 
$6,080,038, and $5,490,281 from a 2 and 5 year timeframe respectively. There was
a decrease in total contraception costs by 3.37%, and 2.26% from both a two and
ﬁ ve year timeframe respectively. Sensitivity analysis showed that LNG-IUS remained
cost-effective up to 3 times the acquisition cost for both a two and ﬁ ve year time 
horizon. CONCLUSIONS: Switching women from tubal ligation to LNG-IUS would
offer signiﬁ cant savings to the health plan, while maintaining a woman’s fertility.
PIH8
COMPARISON OF LEVONORGESTREL INTRAUTERINE SYSTEM
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OBJECTIVES: Non-oral contraceptives, offer greater efﬁ cacy and little potential for 
patient compliance error compared to user dependent products such as oral contracep-
tives (OC). Patient non-compliance and subsequent high failure rates are a potential 
problem in the US. Therefore, use of non-oral contraception with LNG-IUS 
(MIRENA) maybe a cost-effective strategy for a health plan. The study objective is
to compare the cost-effectiveness of LNG-IUS and oral contraceptives (OC) on preven-
tion of pregnancy from a US payer’s perspective. METHODS: A Markov model was 
constructed to simulate cost savings associated with switching 2% of women (N 
2841) requiring contraception from OC (27.5–25.5%) to LNG-IUS (4.3–6.3%). The
study population was based on a 1-million member plan and included females age
18–45 who desire contraception (N  142,031). Method failure (resulting in ectopic 
pregnancy, spontaneous abortion, induced abortion, or birth), adverse events, and
resource utilization were derived from the literature and supplemented with expert
opinion when needed. Contraceptive methods costs were taken from Medi-Span 
Master 2007 Drug Database. Physician service and ofﬁ ce visits costs were obtained 
from the average fees associated with the 2007 Procedural Terminology (CPT) codes.
Both costs and effectiveness were discounted at 3% per year. Model outputs included
pharmacy, medical, side effects, failure, and total costs to the health plan for a two
and ﬁ ve year time horizon. RESULTS: An increase of 2% of LNG-IUS resulted in a
total cost savings of $2,146,663 (0.70%) and $8,952,120 (1.42%) from a two and
ﬁ ve year timeframe respectively. There was a decrease in total contraception, medical,
side effects and failure costs. Sensitivity analysis showed that LNG-IUS remained
cost-effective up to two and six times the acquisition cost from a two and ﬁ ve year 
time horizon respectively. CONCLUSIONS: This study shows that switching women
from OC to LNG-IUS would offer signiﬁ cant savings to the health plan.
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OBJECTIVES: Pneumococcal vaccination schedules vary from 3 doses (2  1) to 4
doses (3  1) across Canadian provinces. We evaluate the effect of the variation in 
dosing strategy on health outcomes, costs, and cost-effectiveness of vaccination with 
the new 10-valent pneumococcal non-typeable Haemophilus inﬂ uenzae protein-D 
conjugate vaccine (PHiD-CV) compared with the 7-valent pneumococcal conjugate
vaccine (PCV-7). METHODS: We developed an age-compartmental, population-based
model to simulate the vaccine effect at steady-state for one year across the whole 
population. Model outputs include clinical endpoints and economic measures. Incre-
mental Cost-Effectiveness Ratios (ICERs) are computed from the health care system 
perspective, calculating the incremental cost for incremental health gain. Productivity
loss is reported separately and not included in the ICER. One-way and probabilistic 
sensitivity analyses were performed to evaluate the robustness of the model to varia-
tions in the underlying parameter assumptions. RESULTS: Vaccination with 4 doses 
of PHiD-CV or PCV-7 would prevent an additional 296 and 222 cases of invasive
pneumococcal disease (IPD) respectively compared with 3 doses. PHiD-CV (2  1) 
would prevent 116,493 more cases of Acute Otitis Media (AOM) than PCV-7 (2 
1), and 94,076 more cases of AOM than PCV-7 (3  1). Furthermore, PHiD-CV (3 
1) would prevent 76,875 more cases of AOM than PHiD-CV (2  1). The incremental 
cost-effectiveness analysis indicates that compared with no vaccination, PHiD-CV (2 
 1) is cost-effective. Compared with PHiD-CV (2  1), PHiD-CV (3  1) is cost-effec-
tive. However, PHiD-CV (less costly and higher health gain) dominates PCV-7. CON-
CLUSIONS: Vaccination with 4 doses of PHiD-CV or PCV-7 offers a higher protection 
against IPD compared with 3 doses. PHiD-CV (2  1) prevents more cases of AOM
compared with both PCV-7 (2  1) and PCV-7 (3  1). PHiD-CV (3  1) offers better 
protection against IPD and AOM compared with a 2  1 schedule. At price parity 
vaccination with PHiD-CV is the dominant strategy. From the societal perspective, 
PHiD-CV (3  1) dominates PHiD-CV (2  1).
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OBJECTIVES: The objective of this study was to estimate the cost effectiveness of 
oral bisphosphonates administered on extended dosing intervals (i.e., monthly or 
weekly instead of daily regimens) in the U.S. Military Health System. METHODS:
Claims data were analyzed for all female patients over age 18 prescribed oral bisphos-
phonates in the Military Health System. Patients were identiﬁ ed as persistent or non-
persistent [deﬁ ned as patients whose proportion of days covered (PDC) was less than
80% during a 1-year period] in a regression model that adjusted for comorbidities,
duration of illness, and demographics. Two hypothetical cohorts (weekly alendronate 
vs monthly ibandronate) were evaluated in the second stage of the model. Total health
care costs for the hypothetical 10,000-patient cohorts were estimated based on frac-
ture rates (persistent group  8.9%, non-persistent group  11%) and treatment costs 
(average $3,053/fracture) obtained from the clinical literature and mean days of 
therapy and drug acquisition costs obtained from claims data. RESULTS: The regres-
sion model predicted persistence probabilities of 45.92% and 41.76%, respectively, 
for patients receiving oral bisphosphonate products dosed monthly versus weekly. This 
improved adherence was projected to result in an additional 9 fractures avoided over
a one-year treatment period with monthly vs. weekly dosing. Treatment given monthly
was estimated to increase 1-year total health care costs by $212 per patient compared 
to weekly treatment. Taking into account pricing of recently available generics for 
alendronate, the incremental cost effectiveness ratio (ICER) analysis resulted in an 
incremental cost of $235,605 per fracture avoided. CONCLUSIONS: The analysis
and model suggest that monthly-dosed bisphosphonate products likely result in
increased persistence and more fractures avoided when compared to weekly bisphos-
phonate treatment, but at a signiﬁ cant cost per fracture avoided.
